Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
losartan + platelet-rich plasma
- Development stage
- Unknown
- Lead developer
- Mostafa Hassanein
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
This therapeutic approach is a combination of the oral angiotensin II receptor antagonist losartan and locally injected autologous platelet-rich plasma (PRP), specifically investigated for the treatment of acute skeletal muscle sports injuries. Losartan, traditionally used as an antihypertensive, is employed here for its anti-fibrotic properties; it antagonizes the angiotensin II type 1 (AT1) receptor, which in turn inhibits the TGF-β1 signaling pathway responsible for fibrous scar formation in injured muscle tissue. By reducing scarring, losartan facilitates more effective muscle regeneration. Platelet-rich plasma (PRP) complements this by providing a concentrated source of autologous growth factors that stimulate cellular proliferation and tissue repair. This combination modality, studied by Mostafa Hassanein, aims to enhance the quality of muscle healing and accelerate functional recovery compared to PRP treatment alone.
- Brand names
- Cozaar
- Other names
- losartan + PRPAutologous platelets rich plasma + oral LOSARTAN administrationLosartan Combination With PRP
02
Targets
GPVI (Platelet glycoprotein VI)AGTR1 (Angiotensin II Type-1 receptor)TGFB1 (Transforming growth factor Beta-1 proprotein)
Beyond the preview
Go deeper on losartan + platelet-rich plasma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on losartan + platelet-rich plasma.